Viridian Therapeutics ( (VRDN) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Viridian Therapeutics’ stock is on the rise following a series of Buy ratings from analysts, spurred by promising developments such as the BLA submission and potential launch of veligrotug for thyroid eye disease. The company’s recent quarterly earnings report revealed significant revenue growth, which has positively impacted stock price targets, despite a notable net loss. Analysts have raised price targets due to strategic moves towards profitability and promising future prospects.
More about Viridian Therapeutics
YTD Price Performance: 53.54%
Average Trading Volume: 1,251,776
Technical Sentiment Signal: Buy
Current Market Cap: $2.9B
For further insights into VRDN stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.